Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/197869
Inhaled corticosteroids for the treatment of COVID-19
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms
Subject
Subject (English)
Citation
Citation
BAFADHEL, Mona, et al. Inhaled corticosteroids for the treatment of COVID-19. European Respiratory Review. 2022. Vol. 31, num. 220099. ISSN 0905-9180. [consulted: 7 of June of 2026]. Available at: https://hdl.handle.net/2445/197869